Subcutaneous enoxaparin with early invasive strategy in patients with acute coronary syndromes

To link to full-text access for this article, visit this link: http://dx.doi.org/10.1016/j.ahj.2003.10.019 Byline: J.P Collet (a), G Montalescot (a), J.L Golmard (b), M.L Tanguy (b), A Ankri (c), R Choussat (a), F Beygui (a), G Drobinski (a), N Vignolles (a), D Thomas (a) Abstract: Subcutaneous enoxaparin during at least 48 hours provides adequate anticoagulation and good clinical results in patients with non-ST-segment elevation acute coronary syndromes undergoing percutaneous coronary intervention (PCI). Author Affiliation: (a) Department of Cardiology, Pitie-SalpA*triere Hospital, Paris, France (b) Department of Biostatistics, Pitie-SalpA*triere Hospital, Paris, France (c) Hemostasis Laboratory, Pitie-SalpA*triere Hospital, Paris, France Article History: Received 10 December 2002; Accepted 17 October 2003